Bupropion Modulation of Dextromethorphan Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dextromethorphan has limited clinical utility due to rapid hepatic metabolism in extensive metabolizers, leading to low plasma concentrations that reduce its therapeutic efficacy as a single agent.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit its metabolism, thereby increasing plasma levels and extending its metabolic lifetime, which can be administered less frequently without loss of efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered as a single agent, then it provides cough suppression and neurological benefits, but rapid hepatic metabolism causes low plasma concentrations that reduce therapeutic efficacy
Solution Approach 1:
The patent introduces bupropion and its metabolites as intermediary substances that modulate the metabolism of dextromethorphan. These intermediaries inhibit hepatic metabolism through CYP2D6 enzyme inhibition, thereby increasing and sustaining plasma concentrations of dextromethorphan without directly affecting its therapeutic action. This mediator approach resolves the contradiction by allowing effective dosing while maintaining reliable therapeutic levels.
Solution Approach 2:
The patent changes the metabolic parameters of dextromethorphan by co-administering bupropion, which alters the clearance rate and half-life of dextromethorphan. This parameter change transforms the rapid metabolism issue into a sustained release effect, maintaining plasma concentrations within the therapeutic window for extended periods and improving overall therapeutic reliability.
2Reliability
If dextromethorphan is administered frequently to maintain plasma levels, then therapeutic efficacy is improved, but dosing complexity and patient compliance decrease
Solution Approach 1:
The patent achieves continuous therapeutic action by extending the metabolic lifetime of dextromethorphan through bupropion co-administration. This continuity allows single or less frequent dosing regimens to maintain effective plasma concentrations throughout the dosing interval, eliminating the need for frequent redosing while preserving therapeutic efficacy. The useful action of cough suppression and neurological benefit continues uninterrupted.
Solution Approach 2:
The patent creates a dynamic dosing system where the combination of dextromethorphan and bupropion produces time-dependent plasma concentration profiles. The bupropion metabolites provide progressive enzyme inhibition over time, dynamically adjusting the clearance rate to maintain optimal concentrations with less frequent dosing, thereby improving ease of operation without sacrificing efficacy.
3Quantity of substance
If the dose of dextromethorphan is increased to overcome rapid metabolism, then plasma levels improve, but adverse events and toxicity risk increase
Solution Approach 1:
The patent changes the metabolic clearance parameter rather than increasing the administered dose. By inhibiting CYP2D6-mediated metabolism with bupropion, the half-life and area under the curve (AUC) of dextromethorphan are extended, allowing achievement of therapeutic plasma concentrations with lower or equal doses, thereby avoiding dose-dependent adverse events and toxicity risks.
Solution Approach 2:
The patent uses bupropion as an intermediary that protects against the harmful effect of rapid metabolism. This intermediary substance modifies the metabolic pathway to favor sustained release of dextromethorphan, achieving adequate plasma concentrations without requiring high doses that would otherwise cause adverse events such as dizziness, nausea, or potential neurotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic efficacy of dextromethorphan by maintaining effective plasma concentrations, allowing for less frequent dosing and improved treatment outcomes for neurological disorders and cough suppression.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit its metabolism
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.